Aged Population and Immunocompromised Patients: Impact on SARS-CoV-2 Variants and Treatment Outcomes

Chavda, Vivek P.; Chhabria, Mahesh T.; Apostolopoulos, Vasso

doi:10.3390/biologics2030013

Cited by 2 publications

(1 citation statement)

References 50 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The illness cannot be treated with a specific antiviral medication, the key to preventing the spread of the disease is to break the chain of transmission [ 5 ]. To decrease the prevalence and mortality rates, mass immunization against the pandemic is used [ 6 , 7 ]. Since the SARS-CoV-2 genome sequence was released on 11 January 2020, more than 150 authority immunization projects were studied.…”

Section: Introductionmentioning

confidence: 99%

mRNA-Based Vaccine for COVID-19: They Are New but Not Unknown!

et al. 2023

Self Cite

View full text Add to dashboard Cite

mRNA vaccines take advantage of the mechanism that our cells use to produce proteins. Our cells produce proteins based on the knowledge contained in our DNA; each gene encodes a unique protein. The genetic information is essential, but cells cannot use it until mRNA molecules convert it into instructions for producing specific proteins. mRNA vaccinations provide ready-to-use mRNA instructions for constructing a specific protein. BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) both are newly approved mRNA-based COVID-19 vaccines that have shown excellent protection and efficacy. In total, there are five more mRNA-based vaccine candidates for COVID-19 under different phases of clinical development. This review is specifically focused on mRNA-based vaccines for COVID-19 covering its development, mechanism, and clinical aspects.

show abstract

Section: Introductionmentioning

confidence: 99%